The Covid Balancing Act for Doctors

My wife’s parents have led a relatively monastic existence since about mid-March. Both are in their 80s and live independently in rural Pennsylvania, maintaining a three-acre property by themselves. My father-in-law, the older of the two, has skirted major medical problems despite a decades-long indiscriminate diet, a testimony to the triumph of genetics over lifestyle…

COVID-19 and dental and dental hygiene students’ career plans

Alexandria, Va., USA — The COVID-19 pandemic has significantly impacted dental education and training. The study “COVID-19 and Dental and Dental Hygiene Students’ Career Plans,” published in the JDR Clinical & Translational Research (JDR CTR), examined the short-term impact of the COVID-19 pandemic on dental hygiene and dental students’ career intentions. An anonymous online survey…

Heading outdoors keeps lockdown blues at bay

A new study has found that spending time outdoors and switching off our devices is associated with higher levels of happiness during a period of COVID-19 restrictions. Previous academic studies have indicated how being outdoors, particularly in green spaces, can improve mental health by promoting more positive body image, and lowering levels of depression and…

COVID-19 accelerates cancer virtual care with quality, convenience and cost savings

Patients and healthcare providers at the Princess Margaret Cancer Centre rated virtual care during COVID-19 as highly satisfactory overall for quality of care and convenience, while at the same time saving patients millions in costs. Research led by Princess Margaret Radiation Oncologist Dr. Alejandro Berlin showed that virtual care can be implemented rapidly and safely…

C-Path PRO Consortium measure used to support an FDA-approved label claim

TUCSON, Ariz., January 7, 2021 — Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium announces that clinical study results using the Consortium’s Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) were recently included in the expanded label for the drug LINZESS® (linaclotide). The DIBSS-C was developed by the PRO Consortium’s Irritable Bowel Syndrome (IBS) Working Group…